Please ensure Javascript is enabled for purposes of website accessibility

World Health Organization Classifies Wuhan Coronavirus as International Health Emergency

By Taylor Carmichael - Jan 30, 2020 at 3:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Around 99% of cases are in China.

The World Health Organization (WHO) has classified the Wuhan Coronavirus as an international health emergency. Over 8,000 people have caught the virus in China, with 170 deaths resulting from it so far. The virus poses a risk of becoming a worldwide pandemic. 

The Centers for Disease Control and Prevention (CDC) reports that the spouse of one of the first U.S. cases has caught the virus, despite having never been to Wuhan. So far people in 19 countries have been affected, but no one has died outside of China. CDC director Robert Redfield said, "We understand that this may be concerning, but based on what we know now, we still believe the immediate risk to the American public is low." 

People wearing face masks in China

Source: Getty Images

 

Markets affected by Wuhan Coronavirus

Airlines are severely curtailing flights in and out of China. United (UAL 2.88%)American Airlines (AAL 3.55%) and Delta (DAL 1.90%) have suspended flights to and from China this week. United is down 13% for the year. Cruise lines have also been hit. Royal Caribbean (RCL 1.09%) is down 11%. 

Shares of smaller vaccination companies have soared. Vir Biotechnology (VIR 1.57%) is up 98% in 2020, and Novavax (NVAX 11.12%) is up 54%.

The good news is that Chinese health authorities have sequenced the virus. The National Institute of Allergy and Infectious Diseases (NIAID) is working with Moderna (MRNA 4.97%) to produce a vaccine. The Coalition for Epidemic Preparedness Innovations (CEPI) is financing the effort. CEPI is also funding a vaccine from Inovio (INO 9.25%)Johnson & Johnson (JNJ 1.13%) is working on a vaccine as well.

Sequencing the virus will speed up vaccination attempts. Anthony Fauci, director of Allergy and Infectious Diseases at the National Institute of Health, says clinical trials could begin in three months. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.52 (1.13%) $2.01
Royal Caribbean Cruises Ltd. Stock Quote
Royal Caribbean Cruises Ltd.
RCL
$35.29 (1.09%) $0.38
United Airlines Holdings, Inc. Stock Quote
United Airlines Holdings, Inc.
UAL
$36.44 (2.88%) $1.02
Delta Air Lines, Inc. Stock Quote
Delta Air Lines, Inc.
DAL
$29.52 (1.90%) $0.55
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.15 (11.12%) $5.72
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.89 (9.25%) $0.16
American Airlines Group Inc. Stock Quote
American Airlines Group Inc.
AAL
$13.13 (3.55%) $0.45
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$25.87 (1.57%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.